VANGUARD GROUP INC - ADAPTIVE BIOTECHNOLOGIES COR ownership

ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 212 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q2 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.2%.

Quarter-by-quarter ownership
VANGUARD GROUP INC ownership history of ADAPTIVE BIOTECHNOLOGIES COR
ValueSharesWeighting
Q3 2023$66,757,280
-17.5%
12,249,042
+1.6%
0.00%0.0%
Q2 2023$80,872,188
-23.5%
12,052,487
+0.6%
0.00%
-33.3%
Q1 2023$105,760,566
+17.4%
11,977,414
+1.6%
0.00%
+50.0%
Q4 2022$90,107,444
+8.4%
11,794,168
+1.0%
0.00%0.0%
Q3 2022$83,104,000
-11.3%
11,671,783
+0.8%
0.00%
-33.3%
Q2 2022$93,654,000
-39.2%
11,576,374
+4.4%
0.00%
-25.0%
Q1 2022$153,941,000
-50.3%
11,090,834
+0.5%
0.00%
-42.9%
Q4 2021$309,537,000
-17.1%
11,031,288
+0.4%
0.01%
-22.2%
Q3 2021$373,573,000
-10.2%
10,990,673
+8.0%
0.01%
-10.0%
Q2 2021$415,859,000
+3.1%
10,177,659
+1.6%
0.01%
-9.1%
Q1 2021$403,485,000
-29.3%
10,021,989
+3.8%
0.01%
-35.3%
Q4 2020$570,925,000
+66.1%
9,655,425
+36.6%
0.02%
+54.5%
Q3 2020$343,625,000
+25.9%
7,066,107
+25.3%
0.01%
+10.0%
Q2 2020$272,933,000
+119.7%
5,641,434
+26.2%
0.01%
+100.0%
Q1 2020$124,225,000
+162.6%
4,471,781
+182.8%
0.01%
+150.0%
Q4 2019$47,305,000
+2.3%
1,581,071
+5.7%
0.00%0.0%
Q3 2019$46,238,000
+378.7%
1,496,386
+648.2%
0.00%
Q2 2019$9,660,000200,0000.00%
Other shareholders
ADAPTIVE BIOTECHNOLOGIES COR shareholders Q2 2022
NameSharesValueWeighting ↓
Blue Water Life Science Advisors, LP 2,377,665$12,958,27412.23%
Eagle Health Investments LP 1,214,860$6,620,9871.46%
Matrix Capital Management Company, LP 11,572,590$63,070,6160.76%
Aristotle Atlantic Partners, LLC 3,058,206$16,667,2230.67%
VIKING GLOBAL INVESTORS LP 29,993,708$163,465,7090.66%
Pier Capital, LLC 719,067$3,918,9150.63%
DDD Partners, LLC 783,697$3,385,5710.49%
ARK Investment Management 11,509,308$62,725,7280.48%
Nikko Asset Management Americas, Inc. 6,570,939$35,680,1990.43%
Triatomic Management LP 102,889$560,7450.39%
View complete list of ADAPTIVE BIOTECHNOLOGIES COR shareholders